|
Video: What is a Stock Split?
|
|
Sesen Bio is a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer. Co.'s main product candidate Vicinium (VB4-845), is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive carcinoma in situ of the bladder in patients previously treated with adequate or less than adequate bacillus Calmette-Guerin. Co.'s lead systemically-administered product candidate, VB6-845d, is being developed as a treatment for multiple types of EpCAM-positive solid tumors. According to our CARM split history records, Carisma Therapeutics has had 1 split. | |
|
Carisma Therapeutics (CARM) has 1 split in our CARM split history database. The split for CARM took place on March 08, 2023. This was a 1 for 20 reverse split, meaning for each 20 shares of CARM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Carisma Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CARM split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Carisma Therapeutics shares, starting with a $10,000 purchase of CARM, presented on a split-history-adjusted basis factoring in the complete CARM split history.
Growth of $10,000.00
With Dividends Reinvested
|
Start date: |
05/01/2014 |
|
End date: |
04/29/2024 |
|
Start price/share: |
$270.80 |
|
End price/share: |
$1.67 |
|
Starting shares: |
36.93 |
|
Ending shares: |
40.56 |
|
Dividends reinvested/share: |
$0.36 |
|
Total return: |
-99.32% |
|
Average Annual Total Return: |
-39.31% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$67.70 |
|
Years: |
10.00 |
|
|
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/01/2014 |
|
End date: |
04/29/2024 |
|
Start price/share: |
$270.80 |
|
End price/share: |
$1.67 |
|
Dividends collected/share: |
$0.36 |
|
Total return: |
-99.25% |
|
Average Annual Total Return: |
-38.69% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$74.94 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
03/08/2023 | 1 for 20 |
|
|